Compare Adaptive Biotechnologies Corp (ADPT) vs GoPro Inc (GPRO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs GoPro Inc — how do they compare? Adaptive Biotechnologies Corp trades at $20.06 (market cap $3.33B), while GoPro Inc trades at $0.72 (market cap $121.79M). The key difference: Adaptive Biotechnologies Corp is far larger — about 27.3× GoPro Inc's market cap, and Adaptive Biotechnologies Corp is trading nearer its 52-week high, GoPro Inc nearer its low. Which is the better fit depends on your goals.
| ADPT | GPRO | |
|---|---|---|
Market Cap | $3.33B | $121.79M |
Sector | Health | Technology |
52-Week High | $22.37 | $2.88 |
52-Week Low | $10.24 | $0.64 |
Enterprise Value | $3.19B | $169.74M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
GoPro (GPRO) trades at $0.701, down 3.96% for the day, reflecting persistent financial distress. The stock shows a bearish technical outlook with negative cash flows and consecutive earnings misses. Recent news highlights a strategic review for potential sale or merger, announced on May 11, 2026, following weak Q1 2026 results. Revenue has declined from $1.1B in 2022 to $652M in 2025, with net losses deepening, indicating significant operational challenges.
The investment outlook remains highly speculative. The strategic sale process offers a potential catalyst, but substantial risks include ongoing cash burn, negative equity, and competitive pressures. Analyst sentiment is mixed with a cautious hold bias. Investors should weigh the binary outcome of a successful strategic transaction against the company's fundamental deterioration and explicit going-concern risks noted in recent disclosures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About GoPro Inc
GoPro Inc is a United States-based company that is principally engaged in designing and providing cameras, mounts, drones and appliances. The company outsources a part of manufacturing to third parties in China. The company sells products across the world through its direct sales channel, which generates over half of total revenue, and indirectly through its distribution channel. The company has presence, including in the Americas, Europe, Middle East, Africa, and Asia-Pacific, with the Americas contributing over half of total revenue.
Read more on GPRO →
